182 related articles for article (PubMed ID: 35918248)
1. Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinoma.
Tripathi N; Jo Y; Tripathi A; Sayegh N; Li H; Nussenzveig R; Haaland B; Thomas VM; Gupta S; Maughan BL; Swami U; Pal SK; Grivas P; Agarwal N; Sirohi D
Urol Oncol; 2022 Nov; 40(11):493.e1-493.e7. PubMed ID: 35918248
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder.
Necchi A; Madison R; Raggi D; Jacob JM; Bratslavsky G; Shapiro O; Elvin JA; Vergilio JA; Killian JK; Ngo N; Ramkissoon S; Severson E; Hemmerich AC; Huang R; Ali SM; Chung JH; Reddy P; Miller VA; Schrock AB; Gay LM; Alexander BM; Grivas P; Ross JS
Eur Urol; 2020 Apr; 77(4):548-556. PubMed ID: 31959546
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
[TBL] [Abstract][Full Text] [Related]
4. Genomic profiling of Chinese patients with urothelial carcinoma.
Yang B; Zhao X; Wan C; Ma X; Niu S; Guo A; Wang J; Wang J; Sun D; Jiao S
BMC Cancer; 2021 Feb; 21(1):162. PubMed ID: 33588785
[TBL] [Abstract][Full Text] [Related]
5. Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin.
Jindal T; Zhang L; Deshmukh P; Reyes K; Chan E; Kumar V; Zhu X; Maldonado E; Feng S; Johnson M; Angelidakis A; Kwon D; Desai A; Borno HT; Bose R; Wong A; Hong J; Carroll P; Meng M; Porten S; Aggarwal R; Small EJ; Fong L; Chou J; Friedlander T; de Kouchkovsky I; Koshkin VS
Clin Genitourin Cancer; 2023 Oct; 21(5):e394-e404. PubMed ID: 37316414
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy.
Tang Q; Zuo W; Wan C; Xiong S; Xu C; Yuan C; Sun Q; Zhou L; Li X
Front Immunol; 2022; 13():1097730. PubMed ID: 36818471
[TBL] [Abstract][Full Text] [Related]
7. HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study.
Ghelani GH; Zerdan MB; Jacob J; Spiess PE; Li R; Necchi A; Grivas P; Kamat A; Danziger N; Lin D; Huang R; Decker B; Sokol ES; Cheng L; Pavlick D; Ross JS; Bratslavsky G; Basnet A
Urol Oncol; 2023 Dec; 41(12):486.e15-486.e23. PubMed ID: 37821306
[TBL] [Abstract][Full Text] [Related]
8. Comparison of structural genetics of non-schistosoma-associated squamous cell carcinoma of the urinary bladder.
Molitor M; Junker K; Eltze E; Toma M; Denzinger S; Siegert S; Knuechel R; Gaisa NT
Int J Clin Exp Pathol; 2015; 8(7):8143-58. PubMed ID: 26339383
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy.
Li Q; Assel M; Benfante NE; Pietzak EJ; Herr HW; Donat M; Cha EK; Donahue TF; Bochner BH; Dalbagni G
Eur Urol Focus; 2019 Jan; 5(1):104-108. PubMed ID: 28753857
[TBL] [Abstract][Full Text] [Related]
10. Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection.
Wasco MJ; Daignault S; Zhang Y; Kunju LP; Kinnaman M; Braun T; Lee CT; Shah RB
Urology; 2007 Jul; 70(1):69-74. PubMed ID: 17656211
[TBL] [Abstract][Full Text] [Related]
11. ARID1A alteration in aggressive urothelial carcinoma and variants of urothelial carcinoma.
Li J; Lu S; Lombardo K; Monahan R; Amin A
Hum Pathol; 2016 Sep; 55():17-23. PubMed ID: 27137986
[TBL] [Abstract][Full Text] [Related]
12. Clinical Significance of Squamous Differentiation in Urothelial Carcinoma of the Bladder.
Minato A; Noguchi H; Tomisaki I; Fukuda A; Kubo T; Nakayama T; Fujimoto N
Cancer Control; 2018; 25(1):1073274818800269. PubMed ID: 30213195
[TBL] [Abstract][Full Text] [Related]
13. Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2.
Posada JM; Yakirevich E; Kamat AM; Sood A; Jacob JM; Bratslavsky G; Grivas P; Spiess PE; Li R; Necchi A; Mega AE; Golijanin DJ; Pavlick D; Huang RSP; Lin D; Danziger N; Sokol ES; Sivakumar S; Ross JS; Cheng L
Mod Pathol; 2024 Mar; 37(3):100424. PubMed ID: 38219954
[TBL] [Abstract][Full Text] [Related]
14. MRI-based automated machine learning model for preoperative identification of variant histology in muscle-invasive bladder carcinoma.
Huang J; Chen G; Liu H; Jiang W; Mai S; Zhang L; Zeng H; Wu S; Chen CY; Wu Z
Eur Radiol; 2024 Mar; 34(3):1804-1815. PubMed ID: 37658139
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.
Ross JS; Wang K; Khaira D; Ali SM; Fisher HA; Mian B; Nazeer T; Elvin JA; Palma N; Yelensky R; Lipson D; Miller VA; Stephens PJ; Subbiah V; Pal SK
Cancer; 2016 Mar; 122(5):702-11. PubMed ID: 26651075
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of GATA-3 in urothelial carcinoma variants.
Liang Y; Heitzman J; Kamat AM; Dinney CP; Czerniak B; Guo CC
Hum Pathol; 2014 Jul; 45(7):1466-72. PubMed ID: 24745616
[TBL] [Abstract][Full Text] [Related]
17. Utility of D2-40, Cytokeratin 5/6, and High-Molecular-weight Cytokeratin (Clone 34βE12) in Distinguishing Intraductal Spread of Urothelial Carcinoma From Prostatic Stromal Invasion.
Iakymenko OA; Briski LM; Delma KS; Jorda M; Kryvenko ON
Am J Surg Pathol; 2022 Apr; 46(4):454-463. PubMed ID: 34560681
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Genomic Characterization in Upper Tract Urothelial Carcinoma and Urothelial Carcinoma of the Bladder.
Yang K; Yu W; Liu H; Ding F; Zhang Y; Zhang Y; Wang W; Lou F; Cao S; Wang H; He Z
Oncologist; 2021 Aug; 26(8):e1395-e1405. PubMed ID: 34050578
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
20. Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital.
Shah RB; Montgomery JS; Montie JE; Kunju LP
Urol Oncol; 2013 Nov; 31(8):1650-5. PubMed ID: 22608543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]